Product
Ipilimumab + Pembrolizumab
Aliases
ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab, Local ICIs.
2 clinical trials
4 indications
Indication
Liver CancerIndication
AntibodyIndication
lung cancerIndication
Inoperable DiseaseClinical trial
Intra-tumor Delivery of Double Checkpoint Inhibitors, Chemodrug, and/or Bevacizumab Therapy as First Line for Hepatocellular CarcinomaStatus: Recruiting, Estimated PCD: 2030-12-30
Clinical trial
Intra-tumor Delivery of Double Checkpoint Inhibitors, Chemodrug, and/or Bevacizumab Therapy as First Line for Inoperable Lung CancerStatus: Recruiting, Estimated PCD: 2028-12-30